BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15087407)

  • 21. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells.
    Kim C; Matsumura M; Saijo K; Ohno T
    Cancer Immunol Immunother; 1998 Oct; 47(2):90-6. PubMed ID: 9769117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes.
    Kikuchi M; Nakao M; Inoue Y; Matsunaga K; Shichijo S; Yamana H; Itoh K
    Int J Cancer; 1999 May; 81(3):459-66. PubMed ID: 10209962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587.
    Li B; Wang Y; Chen J; Wu H; Chen W
    Clin Exp Immunol; 2005 May; 140(2):310-9. PubMed ID: 15807856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
    Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
    Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.
    Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I
    Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients.
    Wang Y; Takao Y; Harada M; Komatsu N; Ono T; Sata M; Itoh K; Yamada A
    Cell Immunol; 2006 May; 241(1):38-46. PubMed ID: 16963008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
    Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
    Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen.
    Zhu B; Chen Z; Cheng X; Lin Z; Guo J; Jia Z; Zou L; Wang Z; Hu Y; Wang D; Wu Y
    Clin Cancer Res; 2003 May; 9(5):1850-7. PubMed ID: 12738743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
    Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
    Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer.
    Hoshino T; Seki N; Kikuchi M; Kuramoto T; Iwamoto O; Kodama I; Koufuji K; Takeda J; Itoh K
    Int J Cancer; 1997 Mar; 70(6):631-8. PubMed ID: 9096641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site.
    Azuma K; Shichijo S; Maeda Y; Nakatsura T; Nonaka Y; Fujii T; Koike K; Itoh K
    Cancer Res; 2003 Feb; 63(4):854-8. PubMed ID: 12591737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
    Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
    Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
    Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
    Cancer Res; 1999 Aug; 59(16):4056-63. PubMed ID: 10463607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
    Dupont J; Latouche JB; Ma C; Sadelain M
    Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
    Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
    Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
    Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
    Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.
    Kono K; Rongcun Y; Charo J; Ichihara F; Celis E; Sette A; Appella E; Sekikawa T; Matsumoto Y; Kiessling R
    Int J Cancer; 1998 Oct; 78(2):202-8. PubMed ID: 9754653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of SART3 tumor-rejection antigen in gastric cancers.
    Niiya F; Nishizaka S; Matsunaga K; Koufuji K; Mori M; Katai H; Yamana H; Itoh K
    Jpn J Cancer Res; 2000 Mar; 91(3):337-42. PubMed ID: 10760694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
    Matsueda S; Takedatsu H; Yao A; Tanaka M; Noguchi M; Itoh K; Harada M
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6933-43. PubMed ID: 16203785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.
    Mimura K; Kono K; Southwood S; Fikes J; Takahashi A; Miyagawa N; Sugai H; Fujii H
    Cancer Immunol Immunother; 2006 Nov; 55(11):1358-66. PubMed ID: 16435129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.